Mochi Health review: the fair-terms pick of the compounded programs
Verdict
~$178/month all-in for compounded semaglutide (~$278 for tirzepatide) with the fairest terms in the compounded group: month-to-month billing, cancel anytime with no fee, and a real 30-minute video visit with a board-certified provider — not just an intake form. Available in all 50 states + DC.
Cancel anytime, no fee Video visit included Compounded meds — not FDA-approved Active Lilly lawsuit
What it actually costs
| Item | Price | Notes |
|---|---|---|
| Membership | $79/mo | $39 first-month promo in eligible states; month-to-month |
| Compounded semaglutide | $99/4 weekly doses | Not FDA-approved; prescribed patient-specifically |
| Compounded tirzepatide | $199/4 weekly doses | Not FDA-approved |
| All-in, semaglutide | ~$178/mo | Flat across doses — no step-up pricing surprise |
| All-in, tirzepatide | ~$278/mo | |
| Branded Wegovy/Zepbound | Membership + med cost | Run through your insurance, or manufacturer self-pay pricing |
The number to compare against: manufacturer-direct branded options run $149/mo (Foundayo, Wegovy pill) to $299–449/mo (Zepbound vials, Wegovy pen) with no membership fee — see our full cost guide. Mochi's case is that ~$178 all-in undercuts most branded injectable routes and includes ongoing provider care.
How it works
Unlike the async-form providers, every Mochi member starts with a scheduled 30-minute video appointment with a board-certified provider, with regular follow-ups after. If you want an actual clinician conversation about dosing, side effects, and whether a GLP-1 makes sense for you, this is the strongest onboarding in the compounded group. If you want medication with minimum friction, an async provider will feel faster.
Where Mochi wins
- Cheapest well-known all-in compounded program (~$178/mo)
- Flat medication pricing across doses — no step-up creep
- Cancel anytime, no fees or commitments (rare in this market)
- Real video visits with board-certified providers
- All 50 states + DC
Where it doesn't
- Compounded semaglutide/tirzepatide are not FDA-approved products
- Eli Lilly's lawsuit over its compounded tirzepatide marketing is active (see below)
- Video-visit requirement means scheduling, not instant signup
- Membership fee applies even in months you're between medications
The red flag, honestly stated
Eli Lilly sued Mochi Health in April 2025 (N.D. Cal.) alleging unfair competition in how its compounded tirzepatide was marketed and prescribed — including whether "personalized" dosing was genuinely patient-specific. The first complaint was dismissed on standing; the amended complaint was cleared to proceed, and the case remains active as of August 2026. Mochi continues to operate in all 50 states. What this means practically: the compounded-GLP-1 pathway itself is under legal pressure industry-wide, and any compounded program you join could be forced to change offerings mid-treatment. Have a plan B (branded transition) whichever compounded provider you choose. Context in our compounded-status explainer.
Who should pick Mochi
Cash-pay patients who've decided — with their own eyes open and ideally their own doctor's input — that a compounded GLP-1's price is worth its trade-offs, and who want the fairest exit terms and real clinician contact while on it. If you'd rather have an FDA-approved medication, compare the manufacturer direct-pay programs first; if monthly price is the only criterion and you accept lock-in risk, Found's 12-month plan lists lower.
Check Mochi's current pricing Back to full comparison